Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients

Prostate

Volumn 73, Issue 1, 2013, Pages 48-53

  Goode, Roland R ^a   Marshall, Susan J ^a   Duff, Michael ^a,b   Chevli, Eric ^c   Chevli, K Kent ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Cancer Care of Western New York   (United States)

^c Western New York Urology Associates   (United States)

Author keywords

biomarker; detection; prostate cancer

Indexed keywords

BIOLOGICAL MARKER; PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; COMPARATIVE STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RECEIVER OPERATING CHARACTERISTIC; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOPSY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 84870565468     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22538     Document Type: Article

References (31)

1. Bunting PS,. Screening for prostate cancer with prostate-specific antigen: Beware the biases. Clin Chim Acta 2002; 315: 71-97. (Pubitemid 33145250)
2. Guinan P, Bhatti R, Ray P,. An evaluation of prostate specific antigen in prostatic cancer. J Urol 1987; 137: 686-689. (Pubitemid 17058681)
3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E,. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916. (Pubitemid 17147932)
4. Raja J, Ramachandran N, Munneke G, Patel U,. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 2006; 61: 142-153. (Pubitemid 43137193)
5. Naughton CK, Miller DC, Mager DE,. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: Impact on cancer detection. J Urol 2000; 164: 388-392. (Pubitemid 30481932)
6. Presti JC, Chang JJ, Bhargava V, Shinohara K,. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial. J Urol 2000; 163: 163-167.
7. Babaian RJ, Toi A, Kamoi K,. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152-157.
8. Sardana G, Dowell B, Diamandis EP,. Emerging biomarkers for diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54: 1951-1960. (Pubitemid 352774027)
9. Ploussard G, de la Taille A,. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7: 101-109.
10. Sokoll L, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chen DW,. A prospective, multicenter, national cancer institute early detection research network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010; 19: 1193-1200.
11. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG,. Are multiple markers the future of prostate cancer diagnostics ? Clin Biochem 2004; 37: 519-528. (Pubitemid 38845015)
12. O'Dowd GJ, Miller MC, Orozco R, Veltri RW,. Analysis of repeated biopsy results within 1 year after a non-cancer diagnosis. Urology 2000; 55: 553-558. (Pubitemid 30157961)
13. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA,. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-5979. (Pubitemid 30004960)
14. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B,. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15.
15. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW,. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-2698. (Pubitemid 34462754)
16. Landers KA, Burger MJ, Tebay MA,. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005; 114: 950-956.
17. Groskopf J, Aubin SM, Deras IL, Blasé A, Bodrug S, Clark C,. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-1095. (Pubitemid 43794421)
18. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA,. Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur Urol 2009; 56: 659-668.
19. Haes A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-1088.
20. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW,. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-1592.
21. Aubin SMJ, Reid J, Sarno MJ,. PCA 3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010; 184: 1947-1952.
22. Hessels D, van Gils M, van Hooij O,. Predictive value of PCA 3 in urinary sediments in determining clinico-pathologic characteristics of prostate cancer. Prostate 2010; 70: 10-16.
23. Ochiai A, Okihara K, Kamoi K,. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol 2011; 18: 200-205.
24. Marks LS, Fradet Y, Deras IL, Balse A, Mathis J, Aubin SMJ,. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2006; 69: 532-535.
25. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C,. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2007; 64: 311-316.
26. van Gils MP, Hessels D, van Hooij O, Jannik SA, Peelen WP, Hanssen SL,. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007; 13: 939-943. (Pubitemid 46340370)
27. de la Taille A, Irani J, Graefen M,. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011; 185: 2119-2125.
28. Ploussard G, Durand X, Xylinas E,. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 422-429.
29. Auprich M, Chun FK, Ward JF,. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96-105.
30. Vlaeminck-Guillem V, Devonec M, Colombel M,. Urinary PCA3 score predicts prostate cancer multifocality. J Urol 2011; 185: 1234-1239.
31. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M,. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010; 58: 727-732.